Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pozelimab and Cemdisiran PK/PD Study in Healthy Japanese Adults
NCT04940364Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2021
- Primary completion
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of pozelimab in paroxysmal nocturnal hemoglobinuria (PNH) and myasthenia gravis (MG) (5 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Concentrations of pozelimab in serum over time up to 20 weeks and Concentrations of cemdisiran in plasma over time up to 20 weeks. Started Aug 2021; status: completed.
02
Drugs
pozelimab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT04940364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04940364.